联合来氟米特与贝那普利治疗难治性肾病综合征的临床观察

目的探讨联合来氟米特与贝那普利方案运用于难治性肾病综合征的有效性和安全性。方法以本院门诊和病房治疗的12例难治性肾病综合征患者，联合来氟米特，贝那普利以及强的松方案治疗16周，观察24h尿蛋白，血生化以及不良反应，以前后对照方式比较该方案的疗效。结果联合来氟米特与贝那普利方案能有效降低24h尿蛋白和血总胆固醇（5．16±3．21）vs（1．35±0．24），（8．71±2．51）vs（5．21±2．35），P〈0．05，提升血清白蛋白（22．37±6．24）vs（36．72±3．68），P〈0．05），16周内缓解率达到91．67％。治疗前后血白细胞没有明显下降（7．66±2．37）×10^9／Lvs（8．12±2．65）×10^9／L，P〉0．05。结论联合来氟米特与贝那普利方案能有效增加难治性肾病综合征的缓解。

Clinical study on the effect of combination of leflunomide and benazepril on treatment refractory nephropathy syndrome

Objective To investigate the curative effect of combination of leflunomide and benazepril on refractory nephrotic syndrome (RNS). Methods Patients with RNS (n=12) were administrated with benazepril, leflunomide and prednisone for 16 weeks. Twentyfour-hour urine protein excretion, serum albumin and side effects were observed during treatment. Results The clinical remission rate was 91.67% in 16 weeks. Both Twentyfour-hour urine protein excretion and serum cholesterol decreased significantly (5.16±3.21) vs (1.35±0.24), (8.71±2.51) vs (5.21±2.35), P<0.05, serum albumin increased significantly (22.37±6.24)vs(36.72±3.68), P<0.05, and no obvious side effects were observed. The remission rate was 91.67% during sixteen weeks the white blood cells were not decreased. Conclusion Combination of leflunomide and benazepril is a safe and effective medicine in treating refractory nephropathy syndrome.